Am J Med Genet A by Patel, Sonali S. et al.
Analysis of Selected Maternal Exposures and Non-Syndromic 
Atrioventricular Septal Defects in the National Birth Defects 
Prevention Study, 1997–2005
Sonali S. Patel1,*, Trudy L. Burns1,2, Lorenzo D. Botto3, Tiffany J. Riehle-Colarusso4, 
Angela E. Lin5,6, Gary M. Shaw7, and Paul A. Romitti2 the National Birth Defects Prevention 
Study
1Department of Pediatrics, Carver College of Medicine, University of Iowa, Iowa City, Iowa
2Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, Iowa
3Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, Utah
4National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control 
and Prevention, Atlanta, Georgia
5Massachusetts Department of Public Health, Massachusetts Center for Birth Defects Research 
and Prevention, Boston, Massachusetts
6Genetics Unit, MassGeneral Hospital for Children, Boston, Massachusetts
7Department of Pediatrics, Stanford University School of Medicine, Stanford, California
Abstract
Although the descriptive epidemiology of atrioventricular septal defects (AVSDs), a group of 
serious congenital heart defects (CHDs), has been recently reported, non-genetic risk factors have 
not been consistently identified. Using data (1997–2005) from the National Birth Defects 
Prevention Study, an ongoing multisite population-based case–control study, the association 
between selected non-genetic factors and non-syndromic AVSDs was examined. Data on 
periconceptional exposures to such factors were collected by telephone interview from 187 
mothers of AVSD case infants and 6,703 mothers of unaffected infants. Adjusted odds ratios 
(aORs) and 95% confidence intervals (CIs) were estimated from logistic regression models. 
Mothers who reported cigarette smoking during the periconceptional period were more likely to 
have infants with AVSDs compared with non-smokers, independent of maternal age, 
periconceptional alcohol consumption, infant gestational age, family history of CHDs, and study 
site (aOR 1.5, 95% CI 1.1–2.4). The association was strongest in mothers who smoked more than 
25 cigarettes/day. In addition, mothers with periconceptional passive smoke exposure were more 
likely to have infants with AVSDs than unexposed mothers, independent of maternal age, active 
periconceptional smoking, infant gestational age, and family history of CHDs (aOR 1.4, 95% CI 
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1.0–2.0). No associations were observed between AVSDs and maternal history of a urinary tract 
infection or pelvic inflammatory disease, maternal use of a wide variety of medications, maternal 
occupational exposure, parental drug use, or maternal alcohol consumption. If the results of this 
preliminary study can be replicated, minimizing maternal active and passive smoke exposure may 
decrease the incidence of AVSDs.
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Introduction
Congenital heart defects (CHDs), with an estimated prevalence of 6–9/1,000 live births, 
constitute a major proportion of clinically significant birth defects and are an important 
component of pediatric cardiovascular disease [Botto et al., 2001a; Hoffman et al., 2004; 
Reller et al., 2008]. Atrioventricular septal defects (AVSDs), also known as atrioventricular 
canal defects or endocardial cushion defects, include a spectrum of defects based on 
deficiency of the atrioventricular septum and/or atrioventricular (AV) valves and account for 
approximately 5–7% of all CHDs [Pierpont et al., 2000; Reller et al., 2008]. These defects 
comprise a group of serious CHDs with circulatory consequences leading to congestive 
heart failure and pulmonary vascular changes early in life. AVSDs occur most commonly in 
the presence of Down syndrome, but can occur in the absence of a chromosomal 
abnormality. Most non-syndromic AVSDs have been considered to be sporadic or the result 
of multifactorial inheritance [Sheffield et al., 1997]. In the largest population-based 
descriptive analysis, non-syndromic AVSDs were identified in 0.8/10,000 live births in the 
National Birth Defects Prevention Study (NBDPS) [Hartman et al., 2011]. Other population-
based studies, such as the Baltimore-Washington Infant Study and the Metropolitan Atlanta 
Congenital Defect Program, have estimated the prevalence of non-Down syndromic AVSDs 
to be 1/10,000 live births [Ferencz et al., 1993; Botto et al., 2001a].
There is an interest in non-genetic risk factors which contribute to the development of 
CHDs; large population-based case–control studies, such as the NBDPS, have attempted to 
address the role that medications and other exposures may play. Numerous risk factors have 
been studied for their association with CHDs, however, very few risk factors have shown a 
significant association with AVSDs. Recent studies have suggested that maternal illnesses, 
medication and non-therapeutic drug use, and maternal and paternal occupational and/or 
environmental exposures may be significantly associated with AVSDs [Jenkins et al., 2007; 
Patel, 2010].
In the Baltimore-Washington Infant Study, a case–control study of CHDs in the 1980s, 
associations were observed between non-syndromic complete AVSDs and family history of 
CHDs, maternal diabetes, antitussive medication use, heavy maternal cigarette use (>20 
cigarettes/day) and cocaine use, parental exposure to varnishes, and paternal exposure to 
ionizing radiation (Table I). A more recent analysis of this dataset identified a suggestive 
Patel et al. Page 2













dose-response association for maternal cigarettes smoked per day and non-syndromic 
AVSDs, although the risk estimate was not statistically significant [Alverson et al., 2011].
Case–control analyses, using data from the NBDPS, have identified other possible risk 
factors for non-syndromic AVSDs including maternal history of urinary tract infection 
during pregnancy, maternal history of diabetes during pregnancy, periconceptional antibiotic 
use, periconceptional opioid analgesic use, and moderate (15–24 cigarettes/day) cigarette 
smoking (Table I). A majority of these identified risk factors have not shown consistent 
associations across non-NBDPSs. All but one prior investigation of NBDPS data were 
performed using earlier versions of the database with fewer years of data, warranting 
additional analyses using a much larger sample size. In addition, the prior analyses were 
performed using all cases of CHDs which were then separated by defect type, of which 
AVSD was one type. However, these analyses did not further stratify the AVSDs based on 
additional defect informationinto component subtypes.
We hypothesized that non-genetic risk factors, such as maternal smoking, alcohol use, 
illness, and medication use, are associated with non-syndromic AVSDs and that such 
associations may differ by AVSD component subtypes.
Materials and Methods
Study Population
Subjects for this study were identified from the NBDPS. Details of case and control infant 
selection are described elsewhere [Yoon et al., 2001; Rasmussen et al., 2003]. Briefly, the 
NBDPS was designed to identify infants with selected major defects and unaffected live 
births to evaluate genetic and environmental factors associated with the occurrence of such 
defects [Yoon et al., 2001]. The ongoing case–control study includes case and control 
infants from birth defect surveillance systems at 10 sites (Arkansas, California, Georgia, 
Iowa, Massachusetts, New Jersey, New York, North Carolina, Texas, and Utah). Cases 
include all live births (all sites), stillbirths (all sites except New Jersey), and elective 
terminations (all sites except Massachusetts and New Jersey).
Case infants are diagnosed with one or more of over 30 major birth defects. Medical record 
information for each case infant is reviewed by clinical geneticists at each NBDPS center to 
determine study eligibility. Deliveries with recognized or strongly suspected chromosomal 
abnormalities or single-gene conditions are excluded. After inclusion, case infants with one 
specific defect are classified by one or more clinical geneticists to establish consistency. 
Detailed methods of CHD classification are described elsewhere [Botto et al., 2007]. Live-
born infants used as controls are randomly selected from birth certificate or birth hospital 
records. Control infants are selected from the same base population as case infants and have 
an estimated date of delivery (EDD) within the same year as case infants.
As part of the NBDPS, mothers of case and control infants complete a detailed structured 
interview that asks about maternal health during the periconceptional period, defined as 1 
month before pregnancy through the end of the first trimester, pregnancy history, prenatal 
care, health behaviors, home environment, maternal occupation and exposures, paternal 
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occupation and exposures, and parental demographics. Interviews are targeted for 
completion within 6 months of the infant's EDD but must be completed no earlier than 6 
weeks and no later than 24 months following the EDD.
As of December 2005, maternal interview reports for 18,961 case and 6,807 control infants 
are included in the database. For this investigation, case and control infants were eligible 
NBDPS participants born from October 1997 to December 2005.
AVSD Case Classification
Case infants were those with an AVSD diagnosed by echocardiogram, cardiac 
catheterization, or surgical or autopsy report before 1 year age and whose mother completed 
the NBDPS interview. In addition to the total AVSD case group, two major AVSD subtype 
groups were defined. AVSD case infants were classified as having either (1) a complete 
AVSD, which was defined as the deficiency of the lower atrial septum and the inlet portion 
of the ventricular septum with a common AV valve or (2) a diagnosis within the spectrum of 
AVSDs—primum atrial septal defect, transitional AVSD, and inlet-type ventricular septal 
defect [Botto et al., 2007]. Hearts with complex single ventricle physiology (i.e., unbalanced 
complete AVSDs) were placed in the complete AVSD group. Within each major component 
subtype, cases in which the defect occurred in isolation (i.e., without an extra-cardiac defect) 
were distinguished as (3) isolated complete AVSDs or (4) isolated spectrum AVSDs.
Study Exposures of Interest
Exposures of interest occurred during the periconceptional period. These exposures included 
maternal active smoke exposure, passive smoke exposure, alcohol use, therapeutic 
medication use, occupational exposures, and maternal and paternal illicit drug use. Active 
smoke exposure was determined by self-report of cigarette use during the periconceptional 
period. Mothers were asked to report the number of cigarettes used per day (from <1 
cigarette/day to >2 packs/day) during each month of the periconceptional period. Data on 
other tobacco products or nicotine replacement were not available. Passive smoke exposure 
was determined by self-report of exposure to environmental tobacco smoke at home or in 
the workplace. Data regarding duration of passive smoke exposure were not available. All 
exposures were coded as dichotomous yes/no variables.
As the frequencies of reported use of individual medications among case mothers were very 
small, medications were collapsed by drug class [Kelley et al., 2003]. Classes of interest 
were classified as: (1) antiinfective medications, including antibacterial, antiviral, and 
antifungal agents; (2) antidepressant medications; (3) asthma and/or allergy medications, 
including bronchodilators, mast-cell stabilizers, leukotriene modifiers, corticosteroids, 
antitussives, expectorants, and antihistamines; (4) gastrointestinal medications, including 
antacids, antidiarrheal agents, antiemetics, antiflatulents, and antiulcer agents; and (5) 
analgesic and antipyretic medications. Similarly, the frequencies of maternal- and paternal-
specific illicit drug use and maternal occupational exposures were also very small, and thus, 
collapsed into dichotomous variables indicating maternal illicit drug use, paternal illicit drug 
use, or maternal occupational exposure during the periconceptional period.
Patel et al. Page 4














All analyses were performed using SAS 9.2 software (SAS Corporation, Cary, NC). Initial 
analyses compared distributions of selected exposures and covariables between AVSD cases 
and control infants. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated to 
measure associations between exposure and infant AVSD occurrence. Multivariable logistic 
regression models were used to adjust for the effects of potential confounding variables. 
Exact methods were used when frequencies were less than five. A P-value less than 0.05 
was considered statistically significant. No adjustments were made for multiple testing.
Potential confounders were selected on the basis of results of bivariable analyses and 
previously published evidence. Family history of CHDs, which was defined as the presence 
of a CHD in a first-degree relative, was included in all models as it has been previously 
shown that a family history of CHDs places a family at increased risk of recurrence [Oyen et 
al., 2009]. It also been observed that non-syndromic AVSDs are associated with the 
presence of a CHD in a first-degree relative (OR 7.0, 95% CI 2.6–18.9) [Ferencz et al., 
1997]. The current standard of care includes treatment of a urinary tract infection (UTI) with 
an antibiotic, a number of which are folate antagonists, and therefore antibiotic use and 
folate intake were included in the final model examining the association between UTI and 
AVSDs [Smaill, 2007]. Other potential confounders and effect modifiers considered 
included study center, maternal age at delivery, paternal age at delivery, maternal race/
ethnicity, paternal race/ethnicity, parity, infant sex, infant gestational age, infant birthweight, 
and family history of birth defects, which was defined as the presence of any birth defect in 
a first-degree relative.
Additional analyses focused on the four separate case subtypes— complete AVSDs, 
spectrum AVSDs, isolated complete AVSDs, and isolated spectrum AVSDs. Each 
component subtype was compared with the control group separately. Component subtype 
analyses were approached in a similar manner as those for all AVSD cases combined; 
univariable and multivariable logistic regression analysis models were fitted to estimate ORs 
and 95% CIs to describe the strength of the association between each of the above exposures 
within each AVSD component subtype.
Results
During the study period, 189 women who had a live-born infant with an AVSD (case 
infants) and 6,807 women who had a live-born infant without any birth defect (control 
infants) were contacted for participation by the NBDPS centers. Excluding 2 case and 104 
control infants with incomplete interviews, there were 187 non-syndromic case and 6,703 
control infants. The case group was consisting of 185 (99%) live births, 1 stillbirth, and 1 
elective termination. Among all case infants, there were 78 (42%) with a complete AVSD, 
of which 65 (83%) were isolated. There were 109 (58%) case infants with a spectrum AVSD 
diagnosis, of which 81 (74%) were isolated.
Maternal and infant characteristics for case and control groups are presented in Table II. 
There were no significant differences between case and control participants with respect to 
maternal age, maternal body mass index, total family income, or infant sex. Infant birth 
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weight and gestational age were significantly correlated (P < 0.0001) and therefore, 
gestational age was retained for modeling.
Mothers of infants with AVSDs were more likely to be primiparous compared with mothers 
of infants without a birth defect, and less likely to have listed their race/ethnicity as Hispanic 
compared with control mothers (Table II). Mothers of case infants were also more likely to 
have completed high school or a technical program; and they were more likely to have been 
employed during their pregnancy in comparison to control mothers. Infants with AVSDs 
were more likely to be premature than control infants. Infants with AVSDs were also more 
likely to have a family history of birth defects and have a family history of CHDs in a first-
degree relative than control infants.
Bivariable analyses by component subtype group produced no significant associations for 
maternal age, race/ethnicity, body mass index, parity, or infant sex; however, in each of the 
subtype groups, mothers of case infants were more likely to have been employed during 
their pregnancy (range of ORs among the four component subtypes 1.7–2.1) and have 
completed training at a technical college (ORs 3.6–5.4) (data not shown). Additionally, case 
infants in each group were more likely to have a family history of birth defects (ORs 1.5–
1.9) and a family history of CHD in a first-degree relative (ORs 4.9–6.9) (data not shown). 
Of note, mothers of infants within the spectrum and isolated spectrum component subtypes 
were more likely to be primiparous compared with control mothers (ORs 2.3–2.9) (data not 
shown).
The association between maternal cigarette smoking and AVSDs was analyzed for all 
AVSDs as well as for each AVSD component subtype (Table III). Approximately 26% of 
mothers of all AVSD cases combined reported active cigarette smoking during the 
periconceptional period (Table III). Case mothers were more likely than control mothers to 
have reported active periconceptional smoking. Similar findings were noted in the complete 
AVSD and isolated complete component subtypes. Results were not substantially different 
after further adjustment for maternal age, maternal race/ethnicity, infant gestational age, 
alcohol consumption during the periconceptional period, family history of CHDs, and study 
site. When the highest level of reported smoking was included in the model, mothers who 
reported heavy smoking (>25 cigarettes/day) during the periconceptional period were more 
likely to have an infant with an AVSD compared with mothers who did not smoke (Table 
IV). This finding was independent of maternal age, maternal race/ethnicity, infant gestation 
age, alcohol consumptions during the periconceptional period, family history of CHDs, and 
study site. Again similar findings were noted in the complete AVSD and isolated complete 
AVSD component subtypes.
Periconceptional exposure to passive cigarette smoke was reported in 34% of mothers of all 
AVSD cases combined (Table III). These case mothers were also more likely than control 
mothers to have reported periconceptional exposure to passive smoke. Similar findings were 
noted in the complete AVSD and isolated complete AVSD component subtypes. 
Associations identified were independent of maternal age, maternal race/ethnicity, infant 
gestational age, active periconceptional smoking, family history of CHDs, and study site.
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There was a significant association between periconceptional active cigarette smoking and 
periconceptional exposure to passive smoke among both case and control mothers (P< 
0.0001), with 73.5% (60.6% control) of active smoking case mothers reporting passive 
exposure compared with 20.4% (17.5% control) of nonsmoking case mothers. The 
combined effects of periconceptional active cigarette smoking and periconceptional 
exposure to passive smoke were also examined; Table V displays the results for the 
complete AVSD component subtype. Mothers who reported both active and passive 
exposures were more likely to have an infant with an AVSD compared with mothers who 
did not report either exposure. A multiplicative active and passive exposure interaction 
effect was not significant (OR 1.4, 95% CI 0.5–3.8) (data not shown).
None of these categories of medications, which included antibacterials, antivirals, 
antifungals, antidepressants, asthma and/or allergy medications, gastrointestinal 
medications, or analgesic and antipyretic medications, demonstrated a significant association 
with AVSDs or AVSD subtypes (Supplemental Table I). Other exposures evaluated 
included history of a UTI or pelvic inflammatory disease, parental illicit drug use, maternal 
occupational exposures including exposure to anesthetic gases, ionizing radiation, heavy 
metals, solvents, pesticides, herbicides, fungicides, or rat poison, and maternal alcohol 
consumption during the periconceptional period. No significant associations were observed 
between these categories and non-syndromic AVSDs or any of the AVSD component 
subtypes (Supplemental Table I).
Discussion
Findings from this population-based case–control study indicate that mothers who had 
infants with AVSDs were more likely to have reported periconceptional cigarette smoking 
than control mothers, particularly for the complete AVSD or isolated complete AVSD 
component subtypes. These findings extend those from a previous investigation using an 
earlier version of the NBDPS data which demonstrated an increased risk of AVSDs ininfants 
of mothers who smoked 15–24 cigarettes a day compared with mothers who did not smoke 
[Malik et al., 2008]. No association between active cigarette smoking and spectrum AVSDs 
or isolated spectrum AVSDs was identified. A recent analysis of the Baltimore-Washington 
Infant Study data identified a possible dose-response relationship between the number of 
cigarettes smoked and non-syndromic AVSDs [Alverson et al., 2011]. The current analysis 
of the most recent NBDPS data did not identify a significant trend, but did demonstrate that 
infants with AVSDs were more likely to be born to mothers who reported heavy smoking 
during the periconceptional period.
As maternal periconceptional smoking has been implicated as a possible risk factor for 
CHDs, it is possible that secondhand smoke exposure or passive smoke exposure may also 
play a role. Individuals exposed to secondhand smoke are subjected to a majority of the 
same constituents as those contained in mainstream smoke, although the pattern and 
amounts of exposure differ [Windham et al., 2000]. Studies of secondhand smoke exposure 
and birth defects have identified increased risks of neural tube defects, cleft lip with/without 
palate, and anorectal atresia [Miller et al., 2009; Li et al., 2010; Suarez et al., 2011].
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This represents the first study to evaluate the association between passive smoke exposure 
and AVSDs. For all AVSDs combined, mothers were more likely to have reported 
periconceptional exposure to passive smoke compared with control mothers. Similar to 
active periconceptional smoking, mothers who had infants with either complete AVSDs or 
isolated complete AVSDs were more likely to have reported periconceptional exposure to 
passive smoke than control mothers. These results suggest that passive smoke exposure may 
be an additional factor to incorporate within primary preventive strategies.
Cigarette smoke contains nicotine, polycyclic aromatic hydrocarbons, tar, carbon particles, 
and carbon monoxide. The mechanisms by which cigarette smoke and/or the chemical 
compounds contained within it might result in AVSDs remain to be elucidated. However, 
given the complexity of cardiovascular development, such mechanisms are likely to involve 
gene–gene, gene–environment, or environment–environment interactions. Endo-thelial nitric 
oxide synthase produces nitric oxide, which plays a role in vasodilatation and in the 
regulation of cell growth and apoptosis. Genetic variants within the nitric oxide synthase 
(NOS) gene are known to be associated with birth defects including cleft lip with/without 
palate, gastroschisis, and limb deficiency defects [Shaw et al., 2005; Carmichael et al., 2006; 
Torfs et al., 2006]. It has also been demonstrated that NOS isoforms are present early in 
embryonic cardiac development [Bloch et al., 1999; Shaw et al., 2005; van Beynum et al., 
2008]. The toxicity of xenobiotics for embryonic tissues depends on the biotransformation 
process during which reactive products are formed (phase I) and detoxified (phase II). 
Several enzymes (and their gene families) are involved in this process including glutathione 
transferases. Genetic polymorphisms of glutathione transferase enzymes, which provide a 
critical defense against toxins, have been shown to be associated with CHD formation 
[Cresci et al., 2011]. These investigations with such gene–environment interaction effects 
demonstrate the importance of additional investigations of the associations between 
structural heart defects, maternal smoking, and genetic variants that may modify the effect 
of smoking on the developing fetal heart.
It is interesting to note the difference in magnitude of ORs and CIs between the complete 
and spectrum AVSD component subtypes throughout this study, which likely reflects the 
fact that the complete AVSD group is a more homogenous group. The AVSD spectrum 
component subtype group is not a clinical diagnostic group, but rather a pragmatic 
classification scheme developed for this investigation. As complete AVSDs and the 
diagnoses within the spectrum AVSD group have structural differences, there may be 
developmental heterogeneity among the groups. If individual defects have developmental 
heterogeneity, there may also be etiologic variation. Such differences warrant further 
investigation of complete AVSDs versus the remainder of the AVSD diagnoses.
No significant associations were observed between AVSDs and antibacterials, antivirals, 
antifungals, antidepressants, asthma and/or allergy medications, gastrointestinal 
medications, analgesic and antipyretic medications, parental illicit drug use, and maternal 
occupational exposures. In prior studies, a significant association was seen between AVSDs 
and antibacterial use and a history of a UTI [Cleves et al., 2008; Crider et al., 2009]. In the 
present study, however, there were insufficient data to assess these potential risk factors.
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The strengths of this study include the use of the NBDPS database, which represents the 
largest population-based, case–control study of major cardiovascular malformations 
conducted in the USA. The NBDPS has a geographically and ethnically diverse population 
which reduces the risk of selection bias. As previously reported, the NBDPS controls are 
similar to all live births in the USA [Cogswell et al., 2009]. The cases are reviewed and 
verified by clinical geneticists improving the accuracy of correct case classification. 
Additionally, there is a rigorous review of the abstracted medical chart data by an expert 
panel of clinicians in order to maximize the homogeneity of case classification.
Limitations of the NBDPS must be considered. A major limitation of this study was small 
sample sizes when cases were separated into component subtype groups. Recall bias was 
also of concern due to the retrospective data collection. Each exposure was determined by 
maternal self-reports without independent validation. Nondisclosure of active smoking 
status likely resulted in an underestimation of the true smoking frequency. A recent study 
identified active smoking non-disclosure rates in pregnant women (22.9%) were higher than 
in non-pregnant women (9.2%) [Dietz et al., 2011]. The classification of CHDs requires 
accurate case review and coding by the clinical geneticist at each center, followed by the 
review of the “heart classifier” who ensures that variant and partial forms, including some 
cases coded as atrial and ventricular septal defects, are classified correctly as an AVSD. 
Miscoding would result in a reduction in the actual numbers. The surveillance method of 
each participating center in the NBDPS also varies. Some centers perform surveillance 
across certain portions of the state, while others include the entire state. This may result in 
under-representation of certain ethnic groups, or socioeconomic classes.
The results of this study have important public health consequences. In this study, 19% of 
the control participants reported cigarette use during the periconceptional period whereas 
25% reported passive smoke exposure at home and/or work, which are consistent with 
national figures [Mathews and Rivera, 2004]. Thus, approximately 1 million infants are 
prenatally exposed to cigarette smoke by maternal smoking each year [Byrd and Howard, 
1995; Tong et al., 2009]. Further investigations are warranted to support the results of this 
preliminary study and confirm that active and passive smoke exposure is associated with 
AVSD.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table II
Characteristics of Case and Control Participants
Variable Case participants (N = 187), N (%) Control participants (N = 6,703), N (%) cOR (95% CI)
Maternal age (years)b
 <18 4 (2.1) 245 (3.7) 0.6 (0.2–1.6)
 18–24 57 (30.5) 1,993 (29.5) 1.0 (0.7–1.4)
 25–34 101 (54.0) 3,519 (52.5) Reference
 ≥35 25 (13.4) 946 (14.1) 0.9 (0.6–1.4)
Maternal race/ethnicitya
 Non-Hispanic White 124 (66.7) 4,011 (60.1) Reference
 Non-Hispanic Black 30 (16.1) 764 (11.5) 1.3 (0.8–1.9)
 Hispanic 24 (12.9) 1,491 (22.3) 0.5 (0.3–0.8)
 Other 8 (4.3) 409 (6.1) 0.6 (0.3–1.6)
Maternal body mass indexa
 Underweight 9 (4.9) 356 (5.5) 0.9 (0.5–1.8)
 Normal 99 (54.1) 3,593 (55.8) Reference
 Overweight/obese 75 (41.0) 2,491 (38.7) 1.1 (0.8–1.5)
Maternal parityb
 Primipara 151 (80.7) 4,939 (73.7) 1.5 (1.1–2.4)
 Multipara 36 (19.3) 1,762 (26.3) Reference
Maternal educationb
 <High school 15 (8.0) 1,128 (16.9) Reference
 High school education 109 (58.3) 3,248 (48.5) 2.5 (1.5–4.4)
 Technical college 13 (7.0) 208 (3.1) 4.7 (2.2–10.0)
 ≥Bachelor's degree 50 (26.7) 2,110 (31.5) 1.8 (1.0–3.2)
Maternal job statusb
 Employed 155 (82.9) 4,825 (72.0) 1.9 (1.3–2.8)
 Not employed 32 (17.1) 1,873 (28.0) Reference
Total family incomea
 <$10,000 27 (15.1) 1,079 (17.9) 0.7 (0.4–1.1)
 $10,000–29,999 54 (30.2) 1,696 (28.1) 0.9 (0.6–1.3)
 $30,000–50,000 42 (23.4) 1,131 (18.7) Reference
 ≥$50,000 56 (31.3) 2,132 (35.3) 0.7 (0.5–1.1)
Infant gestational age (weeks)b
 <37 39 (20.9) 635 (9.5) 2.5 (1.8–3.6)
 ≥37 148 (79.1) 6,067 (90.5) Reference
Infant sexb
 Female 104 (55.6) 3,309 (49.4) 1.3 (1.0–1.7)
 Male 83 (44.4) 3,389 (50.6) Reference
Family history of birth defectsa
 Yes 69 (36.9) 1,717 (25.9) 1.7 (1.2–2.3)
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Variable Case participants (N = 187), N (%) Control participants (N = 6,703), N (%) cOR (95% CI)
 No 118 (63.1) 4,923 (74.1) Reference
Family history of CHDb
 Yes 29 (15.5) 212 (3.2) 5.6 (3.7–8.5)
 No 158 (84.5) 6,491 (96.8) Reference
cOR, crude odds ratio; CI, confidence interval; CHD, congenital heart defects.
Items in bold indicate significant findings.
a
Between 10 and 700 missing responses.
b
Less than 10 missing responses.
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Table V
Active and Passive Smoke Exposure for Complete AVSD Component Subtype
Smoke exposure group Cases, N (%) Controls, N (%) cOR (95% CI) aORa (95% CI)
No active or passive exposures 39 (50.0) 4,470 (66.9) Reference Reference
Active exposure only 5 (6.4) 500 (7.5) 1.2 (0.5–3.0) 1.1 (0.4–2.7)
Passive exposure only 12 (15.4) 946 (14.1) 1.5 (0.8–2.3) 1.6 (0.8–3.1)
Both active and passive exposures 22 (28.2) 768 (11.5) 3.3 (2.0–5.6) 3.1 (1.8–5.3)
AVSD, atrioventricular septal defect; cOR, crude odds ratio; aOR, adjusted odds ratio; CI, confidence interval.
a
Adjusted for maternal age, maternal race/ethnicity, gestational age, family history of congenital heart defects, and study site.
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